CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.46 CNY | -3.20% |
|
-7.02% | -20.88% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,715 | 5,572 | 7,306 | 7,659 | 6,005 | - | - |
| Enterprise Value (EV) 1 | 5,715 | 5,572 | 7,306 | 7,659 | 6,005 | 6,005 | 6,005 |
| P/E ratio | 26.7 x | 23.9 x | 29.7 x | 33.9 x | 21.4 x | 17 x | 13.7 x |
| Yield | - | - | - | 0.91% | - | - | - |
| Capitalization / Revenue | - | 5.45 x | 6.24 x | 6.86 x | 4.23 x | 3.42 x | 2.73 x |
| EV / Revenue | - | 5.45 x | 6.24 x | 6.86 x | 4.23 x | 3.42 x | 2.73 x |
| EV / EBITDA | - | 20.1 x | 22.9 x | 24.2 x | 13.4 x | 11.9 x | 9.39 x |
| EV / FCF | - | - | - | - | 40.6 x | 21.9 x | 15.9 x |
| FCF Yield | - | - | - | - | 2.47% | 4.56% | 6.28% |
| Price to Book | - | 2.43 x | 2.99 x | 2.94 x | 2.15 x | 1.94 x | 1.77 x |
| Nbr of stocks (in thousands) | 1,20,090 | 1,20,090 | 1,20,090 | 1,20,090 | 1,18,999 | - | - |
| Reference price 2 | 47.59 | 46.40 | 60.84 | 63.78 | 50.46 | 50.46 | 50.46 |
| Announcement Date | 29/03/21 | 25/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,023 | 1,171 | 1,117 | 1,418 | 1,757 | 2,200 |
| EBITDA 1 | - | 276.8 | 319 | 316.5 | 449.5 | 505 | 639.5 |
| EBIT 1 | - | 244.2 | 260.6 | 243.9 | 304.5 | 386 | 475 |
| Operating Margin | - | 23.87% | 22.27% | 21.84% | 21.47% | 21.97% | 21.59% |
| Earnings before Tax (EBT) 1 | - | 246.9 | 262 | 243.8 | 306.5 | 387.3 | 476 |
| Net income 1 | 178.2 | 232.4 | 246.5 | 226.3 | 283.7 | 356 | 443 |
| Net margin | - | 22.72% | 21.06% | 20.27% | 20% | 20.26% | 20.14% |
| EPS 2 | 1.780 | 1.940 | 2.050 | 1.880 | 2.363 | 2.963 | 3.685 |
| Free Cash Flow 1 | - | - | - | - | 148 | 273.9 | 376.9 |
| FCF margin | - | - | - | - | 10.44% | 15.59% | 17.13% |
| FCF Conversion (EBITDA) | - | - | - | - | 32.93% | 54.24% | 58.94% |
| FCF Conversion (Net income) | - | - | - | - | 52.19% | 76.94% | 85.08% |
| Dividend per Share | - | - | - | 0.5800 | - | - | - |
| Announcement Date | 29/03/21 | 25/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | 148 | 274 | 377 |
| ROE (net income / shareholders' equity) | - | 10.6% | 10.5% | 8.98% | 10.1% | 11.4% | 12.9% |
| ROA (Net income/ Total Assets) | - | - | - | 7.12% | 7.9% | 9% | 10.3% |
| Assets 1 | - | - | - | 3,180 | 3,591 | 3,956 | 4,301 |
| Book Value Per Share 2 | - | 19.10 | 20.40 | 21.70 | 23.50 | 26.00 | 28.60 |
| Cash Flow per Share 2 | - | 1.230 | 1.270 | 2.290 | 4.880 | 5.230 | 5.950 |
| Capex 1 | - | 256 | 339 | 175 | 144 | 108 | 90 |
| Capex / Sales | - | 25.05% | 28.96% | 15.67% | 10.16% | 6.15% | 4.09% |
| Announcement Date | 29/03/21 | 25/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
50.46
CNY
Average target price
75
CNY
Spread / Average Target
+48.63%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.88% | 854M | |
| +55.10% | 811B | |
| +43.62% | 640B | |
| -7.22% | 353B | |
| +17.82% | 333B | |
| +8.94% | 302B | |
| +16.30% | 246B | |
| +2.41% | 225B | |
| +12.47% | 218B | |
| +8.59% | 168B |
- Stock Market
- Equities
- 688513 Stock
- Financials Chengdu Easton Biopharmaceuticals Co., Ltd.
